BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
FGF21
,
Metabolism of xenobiotics
,
Pseudomonas infection
,
Prostate
,
Doxorubicin
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
KINESIN
(compound)
NextBio Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Taxane resistance in breast cancer after paclitaxel treatment
Naive and memory CD4+ T cells from healthy donors stimulated with anti-CD3 anti-CD28 antibodies
Dendritic cells and macrophages differentiated from normal primary monocytes
Manipulation of RNA helicase A and KIF1Bbeta in a neuroblastoma cell line
RNA cargoes of cytoskeletal motor proteins in S. cerevisiae
Explore Curated Studies Results
Literature
Most Relevant Literature
Identification of key residues that regulate the interaction of kinesins with microtubule ends.
Germanium nanospheres for ultraresolution picotensiometry of kinesin motors.
Smart motors and cargo steering drive kinesin-mediated selective transport.
Temperature-dependent activity of kinesins is regulable.
Molecular dynamics simulation of the nanosecond pulsed electric field effect on kinesin nanomotor.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Open Label, Dose Escalation Trial of Oral Eg5 Kinesin-spindle Inhibitor 4SC-205 in Patients With Adv…
A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer
Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877
SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma
SB-715992 in Treating Patients With Locally Advanced, Recurrent, or Metastatic Liver Cancer
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ